中国医学前沿杂志（电子版）2017，Vol.9Issue(12)：34-37,4.DOI:10.12037/YXQY.2017.12-08
培美曲塞联合顺铂对晚期非小细胞肺癌患者外周血循环肿瘤细胞EGFR表达及预后的影响
Effect of Pemetrexed combined with Cisplatin on EGFR expression in peripheral blood circulating tumor cells and prognosis of patients with advanced non-small cell lung cancer
摘要
Abstract
Objective To investigate the effect of Pemetrexed combined with Cisplatin on epidermal growth factor receptor (EGFR) expression in peripheral blood circulating tumor cell and prognosis in patients with advanced non-small cell lung cancer (NSCLC). Method From January 2014 to January 2016, 102 patients with NSCLC were randomly divided into group A, group B, and group C, 34 cases in each group, group A patients were treated with Pemetrexed combined with Cisplatin, group B patients were treated with Gemcitabine combined with Cisplatin, and group C patients were treated with Docetaxel combined with Cisplatin. The total efficiency, median survival time, progression-free survival, 1 year survival rate and the levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), cytokeratin 19 fragment 21-1(CYFRA21-1)were compared among three groups.The mutation of EGFR gene in peripheral blood circulating tumor cell before and after chemotherapy was compared and analyzed. Result After chemotherapy, the total effective rate of group A was significantly higher than that of group B and group C (P < 0.05), the levels of CEA, CA125 and CYFRA21-1 in the three groups were significantly lower than those before chemotherapy, the CEA, CA-125 and CYFRA21-1 of group A were significantly lower than those in group B and group C (P<0.05); the median survival time of group A was significantly longer than those of group B and group C (P < 0.05), but there were no significant differences of progression-free survival and 1 year survival among the three groups (P>0.05). After chemotherapy, the peripheral blood circulating tumor cell EGFR mutation rate of three groups decreased,but there were no significant differences compared with before chemotherapy (P > 0.05), while there were no significant differences among the three groups. (P>0.05). Conclusion Pemetrexed combined with Cisplatin can effectively improve the curative effect in patients with advanced NSCLC, and the effect on long-term prognosis similar to other chemotherapy, whether can change the EGFR mutation status of circulating tumor cells in peripheral blood is not yet clear.However, the detection of EGFR state to the target before treatment can provide the basis for targeted therapy plan.关键词
非小细胞肺癌/培美曲塞/表皮生长因子受体/预后Key words
Non-small cell lung cancer/Pemetrexed/EGFR/Prognosis引用本文复制引用
叶春晖,陈亮,王继鹏,孟自力..培美曲塞联合顺铂对晚期非小细胞肺癌患者外周血循环肿瘤细胞EGFR表达及预后的影响[J].中国医学前沿杂志（电子版）,2017,9(12):34-37,4.基金项目
江苏省科技计划项目(BS012360) （BS012360）
